MRNA250117C49000
- 0.01
- 0.000.00%
Moderna Newsroom
ETFs Shine As S&P 500 Hits Record High: Top 5 ETFs With Best Gains From Last Week
J.P. Morgan Maintains Moderna(MRNA.US) With Sell Rating, Announces Target Price $40
Moderna Is Maintained at In-Line by Evercore ISI Group
Moderna Analyst Ratings
Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $50
Goldman Sachs Adjusts Price Target on Moderna to $99 From $112, Keeps Buy Rating
Express News | RPT-Buzz-US Stocks Weekly: Starstruck
Express News | Moderna : JP Morgan Cuts Target Price to $40 From $45
Why Moderna Stock Jumped Over 20% This Week
Stargate Project's Healthcare Winners: AI-led Biotechs and Metagenomi
Four Years After Covid-19 Success, MRNA Vaccines Aren't Ready for Bird Flu -- Barrons.com
S&P 500 Posts Weekly Gain Amid Earnings Beats, Start of Trump Presidency
Moderna Options Spot-On: On January 24th, 212.26K Contracts Were Traded, With 724.8K Open Interest
On January 24th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 212.26K options for the day, of which put options accounted for 25.54% of the total transactions,
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads
Moderna Shares Are Trading Higher After the Company Announced It Was Awarded a Tender to Supply Its MRNA COVID-19 Vaccine in the European Union, Norway and North Macedonia.
Why I Don't Believe Larry Ellison's Moderna Stock Hype
Sector Update: Health Care Stocks Decline Premarket Friday
Moderna (MRNA.US) stock price is once again experiencing an upward catalyst! The EU has awarded a contract for the COVID-19 vaccine.
The company has received the latest tender for supplying its COVID-19 vaccine in the EU, Norway, and North Macedonia.
Moderna to Supply COVID-19 Vaccines in EU, Norway
Moderna Extends Gains as EU Offers COVID Vaccine Contract